Amgen Invests in Nanomedicine with BIND Biosciences Collaboration
By Heather Cartwright
Pharma Deals Review: Vol 2013 Issue 1 (Table of Contents)
Published: 22 Jan-2013
DOI: 10.3833/pdr.v2013.i1.1874 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
In its first major deal, BIND Biosciences has formed a collaboration with Amgen to develop and commercialise a kinase inhibitor nanomedicine for the treatment of a range of solid tumours...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS